CANCERS BRONCHIQUES NON A PETITES CELLULES AU STADE AVANCE
ESSAIS TESTANT LE ROLE DU CISPLATINE AU SEIN D’UNE ASSOCIATION DE CHIMIOTHERAPIE


 Précédent Retour au menu principal  Suivant


référence

chimiothérapie

n

(stIV)

% RO

p

SM

p

Georgoulias,

2001 (1)

I. CDDP (80 mg/m²)+docetaxel (100 mg/m²)

205

(129)

35

 

NS

10 m

 

NS

II. Gemci + docetaxel (100 mg/m²)

201

(130)

33

9,5 m

Sculier,

2002 (2)

I.CDDP (50) + Carbo (200) + Ifo

94

tous

23

 

 

NS

24 s

 

 

NS

II.CDDP(50) + Carbo (200) +Gemci

92

29

34 s

III.Ifo + gemcitabine

94

25

30 s

Kosmidis,

2002 (3)

I. Paclitaxel (200 mg/m²) + Carbo (AUC 6)

252

(158)

28

 

0,12

10,4 m

 

0,32

II. Paclitaxel (200 mg/m²) + gemcitabine

257

(148)

35

9,8 m

Greco,

2002 (4)

I. CBDCA (AUC 5)+paclitaxel (200)+ gemci

71

(51)

37

 

 

 

NS

9,2 m

 

 

 

NS

II. CBDCA (AUC 6)+paclitaxel (200)+ VNR

65

(51)

45

8,6 m

III. paclitaxel (200)+ gemci

64

(53)

32

8,7 m

IV. Gemci + VNR

67

(49)

33

10,7 m

Chen,

2002 (5)

I. Carboplatine (AUC 7) + paclitaxel (175)

45

 

40

 

14,1 m

 

II. paclitaxel (175)+ gemci

45

 

40

12,6 m

Gebbia,

2003 (6)

I. CDDP + gemcitabine

138

(73)

34

 

 

 

0.007

8,2 m

 

NS

II. CDDP + vinorelbine

140

(75)

44

9,0 m

III. Ifo + gemcitabine puis CDDP + VNR

60

(33)

19

 

IV. CDDP + VNR puis Ifo + gemcitabine

60

(31)

31

 

Gridelli,

2003 (7)

I. CDDP (80) + VNR

126

80%

 

30

 

 

NS

 

38 s

 

 

0,08

II. CDDP (80) + gemcitabine

126

81%

III. VNR + gemcitabine

251

80%

25

32 s

Alberola,

2003 (8)

I. CDDP (100) + gemcitabine

182

77 %

42

 

 

S

9,3 m

 

 

NS

II. CDDP (100) + gemcitabine + VNR

188

79 %

41

8,2 m

III. gemci + VNR x 3 puis Ifo + VNR x 3

187

81 %

27

8,1 m

Smit,

2003(9)

I. paclitaxel (175) + CDDP (80)

159

(130)

32

 

 

NS

8,1 m

 

 

NS

II. CDDP (80) + gemci

160

(126)

37

8,9 m

III. paclitaxel (175) + gemci

161

(136)

28

6,7 m

Wachters,

2004 (10)

I. CDDP + gemcitabine

119

57%

46%

NS

43 s

0,14

II. Epirubicine + gemcitabine

121

57%

36%

36 s

Yamamoto,

2004 (11)

I. CDDP (80) + docetaxel (60)

51

(40)

37 %

NS

50 s

NS

II. Irinotecan + docetaxel (60)

57

(43)

32 %

46 s

Laack,

2004 (12)

I. CDDP (75 J2) + gemci + VNr

144

(126)

28 %

0,004

32 s

0,73

II. gemci + VNR

143

(125)

13 %

36 s

Stathopoulos,

2004 (13)

I. Paclitaxel (135) + vinorelbine

175

47%

43 %

NS

10 m

NS

II. Paclitaxel (175) + carboplatine (AUC 6)

185

49%

46 %

11 m

Lilenbaum,

2005 (14)

I. gemci + VNR

82

82%

14,6 %

 

7,8 m

 

II. Paclitaxel + carboplatine

83

81%

16,9%

8,6m

Chen,

2005(15)

I. VNR (20 J1,8,15) + gemci (800 J1,8,15)

43

77%

23 %

0,02

9,5 m

NS

II. Idem + CDDP (60 J15)

43

81%

46 %

13,1 m

Pujol,

2005 (16)

I. Gemcitabine + docétaxel (85)

155

79 %

31 %

NS

11,1 m

NS

II. CDDP (100) + vinorelbine

156

86 %

36 %

9,6 m

Georgoulias,

2005 (17)

I. Vinorelbine (30 J1 & 8) + CDDP (80 J8)

204

64%

39 %

0,053

8,6 m

NS

II. Gemcitabine (1 J1 & 8) + docétaxel (80 J8)

209

62%

30 %

9,0 m

Tan,

2005 (18)

I. Gemcitabine + vinorelbine

157

80%

28 %

0,15

11,5 m

0,01

II. Carboplatine (AUC 5) + vinorelbine

159

90%

21 %

8,5 m

Katakami,

2006 (19)

I. Docétaxel (60) + cisplatine (80)

68

73%

23%

NS

11,4 m

NS

II. Docétaxel (60) + gemcitabine

63

75%

27%

13,7 m

Yamamoto,

2006 (20)

I. Carboplatine (AUC 5) + gemcitabine

64

73%

20%

NS

432 j

NS

II. Vinorelbine + gemcitabine

64

73%

21%

385 j

Comella,

2007 (21)

I. Gemci + VNR

110

72

31 %

S

8,8 m

NS

II. Gemci + Taxol

107

65

38 %

11,1 m

III. CDDP (50x2) + gemci + VNR

109

59

46 %

10,2 m

IV. CDDP (50x2) + gemci + Taxol

107

77

49 %

11,2 m

Bidoli,

 2006 (22)

I. Carbo + gemci x 6

49

45

25 %

 

11,9 m

 

II. Carbo + gemci x 3 puis gemci + docétaxel x 3

48

45

25 %

9,2 m

III. Oxaliplatine + gemci x 6

50

42

31 %

11,3 m

Hsu,

2008 (23)

I. CDDP (80) + gemcitabine

41

35

31 %

 

13,2 m

 

II. Gemcitabine + épirubicine

39

38

37 %

21,5 m

Quoix,

2011 (24)

I. Carboplatine + paclitaxel

225

80 %

27%

S

10 ,3 m

S

II. Vinorelbine ou gemcitabine

226

81 %

10 %

 

6,2 m

 

Boni,

2012 (25)

I. Cisplatine + gemcitabine

106

~80 %

 

NS

 

S pour CDDP

NS doublets vs triplets

II. Gemcitabine + vinorelbine

106

 

 

III. Gemci + Ifo + cisplatine

110

 

 

IV. Gemci + Ifo + vinorelbine

111

 

 

Flotten,

2012 (26)

I. gemci + vino

215

85 %

 

 

6,3 m

NS

II. carbo + vino

222

85 %

 

7 m

Morabito,

2013 (27)  I

PS 2

I. CDDP + gemci

28

93 %

52 %

NS

5,9 m

0,039

II. gemci

29

93 %

36 %

3 m

Références
(1) Georgoulias V, Papadakis E, Alexopoulos A, Tsiafaki X, Rapti A, Veslemes M, et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet 2001 May 12;357(9267):1478-84.
(2) Sculier JP, Lafitte JJ, Lecomte J, Berghmans T, Thiriaux J, Florin MC, et al. A three-arm phase III randomised trial comparing combinations of platinum derivatives, ifosfamide and/or gemcitabine in stage IV non-small-cell lung cancer. Ann Oncol 2002 Jun;13(6):874-82.
(3) Kosmidis P, Mylonakis N, Nicolaides C, Kalophonos C, Samantas E, Boukovinas J, et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 2002 Sep 1;20(17):3578-85.
(4) Greco FA, Gray JR, Jr., Thompson DS, Burris HA, III, Erland JB, Barton JH, Jr., et al. Prospective randomized study of four novel chemotherapy regimens in patients with advanced nonsmall cell lung carcinoma: a minnie pearl cancer research network trial. Cancer 2002 Sep 15;95(6):1279-85.
(5) Chen YM, Perng RP, Lee YC, Shih JF, Lee CS, Tsai CM, et al. Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated. Ann Oncol 2002 Jan;13(1):108-15.
(6) Gebbia V, Galetta D, Caruso M, Verderame F, Pezzella G, Valdesi M, et al. Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a prospective randomized phase III trial of the Gruppo Oncologico Italia Meridionale. Lung Cancer 2003 Feb;39(2):179-89.
(7) Gridelli C, Gallo C, Shepherd FA, Illiano A, Piantedosi F, Robbiati SF, et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003 Aug 15;21(16):3025-34.
(8) Alberola V, Camps C, Provencio M, Isla D, Rosell R, Vadell C, et al. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial. J Clin Oncol 2003 Sep 1;21(17):3207-13.
(9) Smit EF, van Meerbeeck JP, Lianes P, Debruyne C, Legrand C, Schramel F, et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975. J Clin Oncol 2003 Nov 1;21(21):3909-17.
(10) Wachters FM, Van Putten JW, Kramer H, Erjavec Z, Eppinga P, Strijbos JH, et al. First-line gemcitabine with cisplatin or epirubicin in advanced non-small-cell lung cancer: a phase III trial. Br J Cancer 2003 Oct 6;89(7):1192-9.
(11) Yamamoto N, Fukuoka M, Negoro SI, Nakagawa K, Saito H, Matsui K, et al. Randomised phase II study of docetaxel/cisplatin vs docetaxel/irinotecan in advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group Study (WJTOG9803). Br J Cancer 2004 Jan 12;90(1):87-92.
(12) Laack E, Dickgreber N, Muller T, Knuth A, Benk J, Lorenz C, et al. Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: from the German and Swiss Lung Cancer Study Group. J Clin Oncol 2004 Jun 15;22(12):2348-56.
(13) Stathopoulos GP, Veslemes M, Georgatou N, Antoniou D, Giamboudakis P, Katis K, et al. Front-line paclitaxel-vinorelbine versus paclitaxel-carboplatin in patients with advanced non-small-cell lung cancer: a randomized phase III trial. Ann Oncol 2004 Jul;15(7):1048-55.
(14) Lilenbaum RC, Chen CS, Chidiac T, Schwarzenberger PO, Thant M, Versola M, et al. Phase II randomized trial of vinorelbine and gemcitabine versus carboplatin and paclitaxel in advanced non-small-cell lung cancer. Ann Oncol 2005 Jan;16(1):97-101.
(15) Chen YM, Perng RP, Shih JF, Tsai CM, Whang-Peng J. A randomized phase II study of vinorelbine plus gemcitabine with/without cisplatin against inoperable non-small-cell lung cancer previously untreated. Lung Cancer 2005 Mar;47(3):373-80.
(16) Pujol JL, Breton JL, Gervais R, Rebattu P, Depierre A, Morere JF, et al. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin. Ann Oncol 2005 Apr;16(4):602-10.
(17) Georgoulias V, Ardavanis A, Tsiafaki X, Agelidou A, Mixalopoulou P, Anagnostopoulou O, et al. Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 2005 May 1;23(13):2937-45.
(18) Tan EH, Szczesna A, Krzakowski M, Macha HN, Gatzemeier U, Mattson K, et al. Randomized study of vinorelbine--gemcitabine versus vinorelbine--carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer 2005 Aug;49(2):233-40.
(19) Katagami N, Takiguchi Y, Yoshimori K, Isobe H, Besscho A, Yoshimura A, et al. Docetaxel in combination with either cisplatin or gemcitabine in unresectable non-small cell lung carcinoma : a randomized phase II study by the Japan Lung Cancer Cooperative Clinical Study Group. J Thorac Oncol 2006;1:447-53.
(20) Yamamoto N, Nakagawa K, Uejima H, Sugiura T, Takada Y, Negoro S, et al. Randomized phase II study of carboplatin/gemcitabine versus vinorelbine/gemcitabine in patients with advanced nonsmall cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) 0104 1. Cancer 2006 Aug 1;107(3):599-605.
(21) Comella P, Filippelli G, De CG, Massidda B, Frasci G, Maiorino L, et al. Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: a phase III randomised trial of the Southern Italy Cooperative Oncology Group (SICOG 0101). Ann Oncol 2007 Feb;18(2):324-30.
(22) Bidoli P, Zilembo N, Cortinovis D, Mariani L, Isa L, Aitini E, et al. Randomized phase II three-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer. An Italian Trials in Medical Oncology study. Ann Oncol 2007 Mar;18(3):461-7.
(23) Hsu C, Kuo SH, Hu FC, Cheng AL, Shih JY, Yu CJ, et al. Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial. Lung Cancer 2008 Dec;62(3):334-43.
(24) Quoix E, Zalcman G, Oster JP, Westeel V, Pichon E, Lavole A, et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet 2011 Sep 17;378(9796):1079-88.
(25) Boni C, Tiseo M, Boni L, Baldini E, Recchia F, Barone C, et al. Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB-IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST). Br J Cancer 2012 Feb 14;106(4):658-65.
(26) Flotten O, Gronberg BH, Bremnes R, Amundsen T, Sundstrom S, Rolke H, et al. Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Group. Br J Cancer 2012 Jul 24;107(3):442-7.
(27) Morabito A, Gebbia V, Di MM, Cinieri S, Vigano MG, Bianco R, et al. Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: the CAPPA-2 study. Lung Cancer 2013 Jul;81(1):77-83.


Retour au début de la page